What is Excision BioTherapeutics?
Excision BioTherapeutics is a San Francisco-based biotechnology enterprise dedicated to the development of CRISPR-based therapies designed to excise viral genomes from infected human cells. Unlike traditional antiviral treatments that merely suppress viral replication, Excision's platform seeks to provide functional cures for chronic infectious diseases. The company's core technology, which has already demonstrated efficacy in animal models for HIV, represents a paradigm shift in how the medical community approaches viral persistence. By integrating advanced gene-editing techniques with rigorous clinical validation, the company is establishing a unique market position at the intersection of synthetic biology and infectious disease management.
How much funding has Excision BioTherapeutics raised?
Excision BioTherapeutics has raised a total of $70M across 2 funding rounds:
Angel/Seed
$10M
Other Financing Round
$60M
Angel/Seed (2017): $10M with participation from Artis Ventures Management Iii
Other Financing Round (2021): $60M led by Artis Ventures Management Iii, Cota Capital, Loreda Holdings, Adjuvant Capital, Norwest Venture Partners, Olive Tree Capital, WRVI Capital, IndusAge Advisors, GreatPoint Energy, and Anzu Partners
Key Investors in Excision BioTherapeutics
Artis Ventures Management Iii
Artis Ventures is a dedicated venture capital fund focused on Tech Bio+Health, investing in innovative data-driven life sciences companies that aim to enhance human health and wellness.
Cota Capital
Cota Capital is an investment firm that focuses on early-stage technology companies addressing innovative challenges in the enterprise sector, combining financial investment with deep operational expertise.
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors, providing strategic support to accelerate growth.
What's next for Excision BioTherapeutics?
With the recent capital injection, Excision BioTherapeutics is poised to advance its lead candidates through critical clinical milestones. The strategic focus will likely center on expanding its intellectual property portfolio and optimizing the delivery mechanisms for its CRISPR-based interventions. As the company matures, the emphasis will shift toward navigating complex regulatory pathways and establishing manufacturing capabilities that can support large-scale clinical trials. Investors are closely monitoring the firm's ability to translate its preclinical success into human clinical data, which will serve as the primary catalyst for future valuation growth and potential strategic partnerships within the broader pharmaceutical ecosystem.
See full Excision BioTherapeutics company page
